Business Operations

Through a diversified and differentiated business model of marketing, out-licensing with supply agreements and contract manufacturing, Intas has achieved PAN India presence. Intas’ core strategy in India has been to leverage its hospital network for own/in the licensed pipeline of injectables and target marketing of oral generics in markets of North/West India. The acquisition of Actavis Tamil Nadu and Karnadaka business in 2016 catapulted Intas amongst the top 3 players in the Tamil Nadu and Karnataka Generics market.

In total, Intas has 8,500+ product registrations in the Indian market and strong product pipeline for day 1 launch of products in the market. Intas is a leader in the oncology market with a supportive product basket for every stage and indication. 

Intas’ exceptional Indian pipeline consists of a complex product portfolio. Over 4000 product launches including exclusive 60 day 1 launches are planned in the next 5 years.